ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Repros Therapeutics Inc. (RPRX) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Repros Therapeutics Inc. (RPRX)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Pharmaceuticals
Competitors: PTIE, MRK, LCI, AKRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Repros Therapeutics Inc.© quotemedia

Company Profile

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders. Its primary product candidate includes Androxal, an orally active proprietary small molecule compound that has completed Phase IIb study in men, which normalizes testicular function for the treatment of low testosterone due to secondary hypogonadism; and has completed a Phase II clinical trial for the treatment of hypogonadal men with type 2 diabetes. The company also offers Proellex that acts as a selective blocker of the progesterone receptor in women for the treatment of symptoms associated with uterine fibroids and endometriosis. In addition, it provides phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

Recent News: Repros Therapeutics Inc.